Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREND: Ranibizumab Treat-and-Extend vs Monthly in nAMD
NCT01948830Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Primary completion
- Nov 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Dec 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01948830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01948830.